(Invented) Name Strength Pharmaceutical form. Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml. 2.5 mg prolonged-release capsule, hard

Size: px
Start display at page:

Download "(Invented) Name Strength Pharmaceutical form. Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml. 2.5 mg prolonged-release capsule, hard"

Transcription

1 Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1

2 Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml oral drops, solution ratiopharm Arzneimittel Vertriebs-GmbH, Albert-Schweitzer- Gasse 3, A-1140 Vienna DHE "ratiopharm" 2,5 mg - Kapseln 2.5 mg prolonged-release ratiopharm Arzneimittel Vertriebs-GmbH, Albert-Schweitzer- Gasse 3, A-1140 Vienna DHE "ratiopharm" 5 mg - Kapseln 5 mg prolonged-release Amdipharm Ltd. 3, Burlington Road,, Dihydergot 2,5 mg - Tabletten 2.5 mg tablet WABOSAN Arzneimittelvertriebs GmbH, Anton Anderer Platz 6/1, A-1210 Vienna Ergovasan 2 mg/ml - Tropfen 2 mg/ml oral drops, solution WABOSAN Arzneimittelvertriebs GmbH, Anton Anderer Platz 6/1, A-1210 Vienna Ergovasan 2,5 mg retard - Kapseln 2.5 mg prolonged-release 2

3 Belgium Belgium Finland WABOSAN Arzneimittelvertriebs GmbH, Anton Anderer Platz 6/1, A-1210 Vienna Burlington Road, 3 Laboratoires Belges PHARMACOBEL SA Avenue de Scheut Brussels Belgium PIERRE FABRE MEDICAMENT 45, place Abel Gance Boulogne Billancourt PIERRE FABRE MEDICAMENT 45, place Abel Gance Boulogne Billancourt Ergovasan 5 mg retard - Kapseln 5 mg prolonged-release Dihydergot Forte 2,5 mg Tablet Dystonal 2,5 mg Tablet ORSTANORM 2.5 mg tablet IKARAN L.P. 5 mg, comprimé à libération prolongée IKARAN, solution buvable en gouttes 5 mg prolonged-release tablet 0.20 g /100 ml oral drops, solution 3

4 UCB PHARMA 420 Avenue Estienne d'orves Défense Ouest Colombes UCB PHARMA 420 Avenue Estienne d'orves Défense Ouest Colombes UCB PHARMA 420 Avenue Estienne d'orves Défense Ouest Colombes Alfa Wasserman Pharma SAS 67 rue Anatole, Levallois Perret AMDIPHARM 3, Burlington Road DUBLIN 4 IRELAND AMDIPHARM 3, Burlington Road DUBLIN 4 SEGLOR 2 mg/ml, solution buvable en gouttes 2 mg/ml oral solution SEGLOR 5 mg, gélule 5 mg hard capsule SEGLOR LYOC 5 mg, lyophilisat oral 5 mg oral lyophilisate TAMIK, capsule 3 mg soft capsule DIHYDROERGOTAMINE AMDIPHARM 2 mg/ml, solution buvable DIHYDROERGOTAMINE AMDIPHARM 3 mg, comprimé 2 mg/ml oral solution 3 mg tablet 4

5 Temple Chamcers, 3 Burlington Road IRL- Dihydergot plus Lösung zum Einnehmen 2 mg/ 1 ml 10 mg/ 1 ml Solution Boehringer Ingelheim Pharma GmbH & Co.KG Binger Str. 173 D Ingelheim Effortil plus 0.2 g/ 100 ml 1 g/ 100 ml Solution CT Arzneimittel GmbH Lengeder Str. 42 a D Berlin CT Arzneimittel GmbH Lengeder Str. 42 a D Berlin DET MS Tropflösung 2 mg/ 1 ml Solution Ergotam-CT 2,5mg Retardkapseln Ergotam-CT 5,0mg Retardkapseln 2.5 mg Prolonged-released capsule 5 mg Prolonged-released capsule UCB Pharma GmbH Alfred-Nobel-Str. 10 D Monheim Verla-Pharm Arzneimittel GmbH & Co.KG Hauptstr. 98 D Tutzing Agit depot sanol 5 mg Prolonged-released Verladyn 2 mg/ 1 ml solution 5

6 Greece Luxembourg Amdipharm Ltd.,, Teofarma srl Via Fratelli Cervi, Valle Salimbene Pavia Teofarma srl Via Fratelli Cervi, Valle Salimbene Pavia Acarpia - Servicos Farmaceuticos LDA Rua dos Murcas, 88 Funchal Madeira - Portugal Pierre Fabre Médicaments 45, PLACE ABEL GANCE F BOULOGNE CEDEX Dihydergot 2.5 mg tablet DIIDERGOT 2 mg/ml oral solution DIIDERGOT 3 mg tablet SEGLOR 5 mg modifiedreleasecapsule, hard Ikaran 0.20 g /100 ml oral solution Luxembourg Pierre Fabre Médicaments 45, PLACE ABEL GANCE F BOULOGNE CEDEX Ikaran L.P. 5 mg tablets 6

7 Poland Farmaceutyczna Spółdzielnia Pracy FILOFARM ul. Pułaskiego Bydgoszcz Poland Poland Farmaceutyczna Spółdzielnia Pracy FILOFARM ul. Pułaskiego Bydgoszcz Poland Portugal Laboratórios Azevedos - Indústria Farmacêutica, S.A. PRT Edifícios Azevedos - Estrada Nacional 117-2, Alfragide Amadora Portugal Dihydroergotaminum Filofarm 2 mg/g oral solution DHE - tar 1 mg tablet Seglor Retard 5 mg Prolonged-release Slovenia Spain LEK farmacevtska družba d.d., Verovskova 57, SI-1526 Ljubljana, Slovenia Ditamin 2,5 mg tablete 2,5 mg tablet DIHYDERGOT COMPRIMIDOS 1 mg tablet 7

8 Sweden Sweden Orstanorm 2,5 mg Tablets Orstanorm 5 mg Tablets 8

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma

More information

Member State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration

Member State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing autorisation Holder

More information

(Invented) Name Strength Pharmaceutical form. Ergomed - Tropfen (1:1:1) ERSILAN 1mg/ml Oral drops, solution oral use mg/19.

(Invented) Name Strength Pharmaceutical form. Ergomed - Tropfen (1:1:1) ERSILAN 1mg/ml Oral drops, solution oral use mg/19. Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states 1 Member State (in EEA) Marketing

More information

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria

More information

Orlistat EG 60 mg capsule, hard oral use. Orlistat EG 120 mg capsule, hard oral use. Orlistat Sandoz 60 mg capsule, hard oral use

Orlistat EG 60 mg capsule, hard oral use. Orlistat EG 120 mg capsule, hard oral use. Orlistat Sandoz 60 mg capsule, hard oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATIONS AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Belgium Belgium Belgium Belgium

More information

Product name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln. Awegal inject 164,5 mg / 3 ml

Product name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln. Awegal inject 164,5 mg / 3 ml Annex I List of the names, pharmaceutical s, strengths of the medicinal products, route of, marketing authorisation s in the Member States 1 Bulgaria Estonia Zentiva k.s. 130 U kabelovn Prague 10237 Czech

More information

(Invented) Name Strength Pharmaceutical form

(Invented) Name Strength Pharmaceutical form ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Austria Austria Austria

More information

Member State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV

Member State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State Marketing Authorisation

More information

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of and marketing authorisation holders in the Member s 1 Austria Austria Austria Austria Belgium Belgium Belgium

More information

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection 07 March 2013 EMA/147828/2013 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation holders in the member states

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 SEGLOR 5 mg, hard capsule B/30 (CIP code: 321 899-8) SEGLOR LYOC 5 mg, oral lyophilisate B/30 (CIP code:

More information

Please note that this draft Annex I will be updated to amend information on concerned products/mahs

Please note that this draft Annex I will be updated to amend information on concerned products/mahs 22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 TAMIK Ge 3 mg, soft capsule B/60 (CIP code: 322 714-1) Applicant: IPRAD dihydroergotamine mesylate ATC

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 IKARAN LP 5 mg, tablets B/30 (CIP: 339 287-4) IKARAN Ge 2 mg/ml, oral solution in drops Vial of 50 ml

More information

Amoxicillin 40 mg Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg

Amoxicillin 40 mg Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of applicant/marketing authorisation holder in the member states 1/10 Member State EU/EEA

More information

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal

More information

INN Product name Strength Pharmaceutical form

INN Product name Strength Pharmaceutical form Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation (s) in the member states 1 Targin 10 mg/5 mg prolongedrelease Targin 20 mg/10

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Member State Marketing Authorisation Holder Invented Name Strength Pharmaceutical Route of administration

Member State Marketing Authorisation Holder Invented Name Strength Pharmaceutical Route of administration ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing

More information

4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection

4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Route of ) Austria Bulgaria Cyprus Cyprus Czech Republic

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form Route of administration. BufloMed 'S.Med' 300 mg Filmtabletten

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form Route of administration. BufloMed 'S.Med' 300 mg Filmtabletten Annex I List of the invented names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states 1 Member State EU/EEA Marketing

More information

Sortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten

Sortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State EU/EEA Austria Austria

More information

Package leaflet: Information for the patient. Valotix 500 mg Film-Coated Tablets Valaciclovir

Package leaflet: Information for the patient. Valotix 500 mg Film-Coated Tablets Valaciclovir Package leaflet: Information for the patient Valotix 500 mg Film-Coated Tablets Valaciclovir Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Member State Marketing Authorisation Holder Invented name Strength Pharmaceutical Form Route of administration

Member State Marketing Authorisation Holder Invented name Strength Pharmaceutical Form Route of administration ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES CHMP/309507/2007 1/6 EMEA

More information

Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro

Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices

More information

Smokefree Policies in Europe: Are we there yet?

Smokefree Policies in Europe: Are we there yet? Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially

More information

Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH

Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Austria Austria Austria

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. DRYNOL 20 MG TABLETS bilastine

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. DRYNOL 20 MG TABLETS bilastine PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DRYNOL 20 MG TABLETS bilastine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you only.

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)

PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin) The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 15 June 1999 EMEA/18046/99 PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

Package leaflet: Information for the user Arlevert 20 mg/40 mg tablets cinnarizine/dimenhydrinate

Package leaflet: Information for the user Arlevert 20 mg/40 mg tablets cinnarizine/dimenhydrinate Package leaflet: Information for the user Arlevert 20 mg/40 mg tablets cinnarizine/dimenhydrinate Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER

ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER January 2007 1/5 Member State Applicant or Marketing Authorisation

More information

Tadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler

Tadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation s in the member states 1 Austria Forest Pharma B.V. Newtonlaan

More information

Package leaflet: Information for the patient. Amlode 5 mg Tablets Amlode 10 mg Tablets. amlodipine

Package leaflet: Information for the patient. Amlode 5 mg Tablets Amlode 10 mg Tablets. amlodipine Package leaflet: Information for the patient Amlode 5 mg Tablets Amlode 10 mg Tablets amlodipine Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE ANNEX I ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 4 A. MANUFACTURING AUTHORISATION HOLDERS Manufacturers

More information

Member State Marketing Authorisation Holder Product Name Strength Pharmaceutical Form Route of administration

Member State Marketing Authorisation Holder Product Name Strength Pharmaceutical Form Route of administration ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing Authorisation

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the user. Zirtek 1 mg/ml oral solution. Cetirizine dihydrochloride

Package leaflet: Information for the user. Zirtek 1 mg/ml oral solution. Cetirizine dihydrochloride Package leaflet: Information for the user Zirtek 1 mg/ml oral solution Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

PACKAGE LEAFLET For medicinal products available on prescription

PACKAGE LEAFLET For medicinal products available on prescription PACKAGE LEAFLET PACKAGE LEAFLET For medicinal products available on prescription Package leaflet: Information for the user Zirtek 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet

More information

(Invented) name Strength Pharmaceutical Form Route of administration. Losec 10mg Kapseln 10 mg capsule, hard Oral use

(Invented) name Strength Pharmaceutical Form Route of administration. Losec 10mg Kapseln 10 mg capsule, hard Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Marketing Authorisation

More information

Free Trial Future Generics Database

Free Trial Future Generics Database API Atazanavir Structure O 2 C N H O H N OH N NH O N H N CO2 Brand REYATAZ (BMS : World) Indication Antiviral Originator Ciba-Geigy (Novartis) Developer / Licensee BMS Comments Atazanavir is an azapeptide

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

Product Name Strength Pharmaceutical Form. Valproat-Ratiopharm Chrono 300 mg. Valproat-Ratiopharm Chrono 500 mg

Product Name Strength Pharmaceutical Form. Valproat-Ratiopharm Chrono 300 mg. Valproat-Ratiopharm Chrono 500 mg ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES (EU/EEA) 1 Member State (EU/EEA) Czech

More information

PACKAGE LEAFLET For medicinal products available on prescription

PACKAGE LEAFLET For medicinal products available on prescription PACKAGE LEAFLET PACKAGE LEAFLET For medicinal products available on prescription Package leaflet: Information for the user Zirtek 1 mg/ml oral solution Cetirizine dihydrochloride Read all of this leaflet

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tetmodis 25 mg tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tetmodis 25 mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER Tetmodis 25 mg tablets {Tetrabenazine} Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Page 1 of 5 Package leaflet: Information for the patient Xyzal 5 mg/ml oral drops, solution For adults and children aged 2 years and above Levocetirizine dihydrochloride Read all of this leaflet carefully

More information

Product name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln

Product name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State (in EEA) Marketing authorisation

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the patient. Telmisartan Rowex 40 mg Tablets Telmisartan Rowex 80 mg Tablets. telmisartan

Package leaflet: Information for the patient. Telmisartan Rowex 40 mg Tablets Telmisartan Rowex 80 mg Tablets. telmisartan Package leaflet: Information for the patient Telmisartan Rowex 20 mg Tablets Telmisartan Rowex 40 mg Tablets Telmisartan Rowex 80 mg Tablets telmisartan Read all of this leaflet carefully before you start

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Sevelamer Carbonate Rowex 800mg Film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

Good Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014

Good Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014 Good Laboratory Practice EU-Serbia screening meeting Brussels, 19 June 2014 Table of contents 1. Background information on the principles of GLP 2. EU legal basis for GLP 3. Role of Member States 4. Role

More information

Package leaflet: Information for the patient. CINQAERO 10 mg/ml concentrate for solution for infusion reslizumab

Package leaflet: Information for the patient. CINQAERO 10 mg/ml concentrate for solution for infusion reslizumab Package leaflet: Information for the patient CINQAERO 10 mg/ml concentrate for solution for infusion reslizumab This medicine is subject to additional monitoring. This will allow quick identification of

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin

PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need

More information

ANNEX I LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, PHARMACEUTICAL FORMS, STRENGTHS, ROUTE OF ADMINISTRATION,

ANNEX I LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, PHARMACEUTICAL FORMS, STRENGTHS, ROUTE OF ADMINISTRATION, ANNEX I LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, PHARMACEUTICAL FORMS, STRENGTHS, ROUTE OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATE 1 SERTINDOLE

More information

Package leaflet: information for the user. Ondansetron 4 mg Film-Coated Tablets Ondansetron 8 mg Film-Coated Tablets

Package leaflet: information for the user. Ondansetron 4 mg Film-Coated Tablets Ondansetron 8 mg Film-Coated Tablets Package leaflet: information for the user Ondansetron 4 mg Film-Coated Tablets Ondansetron 8 mg Film-Coated Tablets Ondansetron (as hydrochloride dihydrate) Read all of this leaflet carefully before you

More information

This document is a preview generated by EVS

This document is a preview generated by EVS TECHNICAL REPORT RAPPORT TECHNIQUE TECHNISCHER BERICHT CEN/TR 17223 March 2018 ICS 03.100.70; 11.040.01 English version Guidance on the relationship between EN ISO 13485: 2016 (Medical devices - Quality

More information

Member State Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration

Member State Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing Authorisation

More information

MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa

MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa MENTAL HEALTH CARE OECD HCQI Expert meeting 17 th of May, 2013 Rie Fujisawa Mental health indicators Any hospital readmissions for patients with schizophrenia Same hospital readmissions for patients with

More information

Applicant/MAH (Invented) Name Strength Pharmaceutical Form. Fentanyl STADA Depotpflaster. Fentanyl EG Pleister voor transdermaal gebruik

Applicant/MAH (Invented) Name Strength Pharmaceutical Form. Fentanyl STADA Depotpflaster. Fentanyl EG Pleister voor transdermaal gebruik ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS AND MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES 1 Member State Marketing

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 Karvezide 150/12.5 mg tablets Irbesartan/hydrochlorothiazide PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TO TAKE YOUR TABLETS Your doctor has prescribed this medicine for you.

More information

Package leaflet: Information for the user. Zirtek Allergy 1 mg/ml oral solution. Cetirizine dihydrochloride

Package leaflet: Information for the user. Zirtek Allergy 1 mg/ml oral solution. Cetirizine dihydrochloride Package leaflet: Information for the user Zirtek Allergy 1 mg/ml oral solution Cetirizine dihydrochloride Read all of this leaflet carefully before you start using this medicine because it contains important

More information

ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX

ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX B. PACKAGE LEAFLET 2 NAME OF THE MEDICINAL PRODUCT OLANSEK 2.5 mg TABLETS (OLANZAPINE) GENERAL ADVICE Please read this information carefully before you start

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Vatan 40 mg Film-Coated Tablets Vatan 80 mg Film-Coated Tablets Vatan 160 mg Film-Coated Tablets Vatan 320 mg Film-Coated Tablets valsartan Read all of this

More information

Tiorfan Hidrasec Tiorfix Tiorfast 100 mg PACKAGE LEAFLET

Tiorfan Hidrasec Tiorfix Tiorfast 100 mg PACKAGE LEAFLET Tiorfix Tiorfast 100 mg PACKAGE LEAFLET 1 Tiorfix Tiorfast 100 mg Package leaflet: Information for the user 100 mg hard capsules Racecadotril Read all of this leaflet carefully before you start taking

More information

Package leaflet: Information for the patient. Avodart 0.5 mg soft capsules dutasteride

Package leaflet: Information for the patient. Avodart 0.5 mg soft capsules dutasteride Package leaflet: Information for the patient Avodart 0.5 mg soft capsules dutasteride Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Product name Strength Pharmaceutical form. Myolastan 50 mg - Filmtabletten. Tetrazepam-MIP 50 mg Tabletten

Product name Strength Pharmaceutical form. Myolastan 50 mg - Filmtabletten. Tetrazepam-MIP 50 mg Tabletten Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation holders in the Member States 1 Member State (in EEA) Marketing

More information

Package leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol

Package leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol Package leaflet: Information for the patient Paracetamol Read all of this leaflet carefully before you are given this medicine because it contains important information for you. - Keep this leaflet. You

More information

Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data

Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data 29 November 2012 EMA/764460/2012 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation s in the member states for

More information

Decentralised Procedure. Public Assessment Report

Decentralised Procedure. Public Assessment Report Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Clozapin Regiomedica 50 mg/ml Suspension zum Einnehmen Clozamedica 50 mg/ml Suspension zum Einnehmen

More information

Lescol 20 mg - Kapseln 20 mg Capsule, hard Oral use. Lescol 40 mg - Kapseln 40 mg Capsule, hard Oral use

Lescol 20 mg - Kapseln 20 mg Capsule, hard Oral use. Lescol 40 mg - Kapseln 40 mg Capsule, hard Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Marketing Authorisation

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Calcium Sandoz 500 mg, effervescent tablets Calcium Sandoz 1000 mg, effervescent tablets Calcium Read all of this leaflet carefully because it contains important

More information

Package leaflet: Information for the patient. Tamnexyl XL 400micrograms Prolonged-release Tablets. Tamsulosin hydrochloride

Package leaflet: Information for the patient. Tamnexyl XL 400micrograms Prolonged-release Tablets. Tamsulosin hydrochloride Package leaflet: Information for the patient Tamnexyl XL 400micrograms Prolonged-release Tablets Tamsulosin hydrochloride Read all of this leaflet carefully before you start taking this medicine because

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Xyzal 5 mg/ml oral drops, solution Page 1 of 5 Package leaflet: Information for the patient Xyzal 5 mg/ml oral drops, solution For adults and children aged 2 years and above Levocetirizine dihydrochloride

More information

Invented name Strength. 125mg/5ml. 250mg/5ml

Invented name Strength. 125mg/5ml. 250mg/5ml Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States Member State (EU/EEA) Marketing Authorisation

More information

Package leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate

Package leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate Package leaflet: Information for the patient Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate Read all of this leaflet carefully before you are given this medicine because

More information

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Always

More information

Legal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS

Legal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS Legal Supplement Part B Vol. 57, No. 6 18th January, 2018 11 LEGAL NOTICE NO. 5 REPUBLIC OF TRINIDAD AND TOBAGO FOOD AND DRUGS ACT, CHAP. 30:01 NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS ISSUED

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

Amidex 1 mg film-coated tablets

Amidex 1 mg film-coated tablets Package leaflet: Information for the user Amidex 1 mg film-coated tablets Anastrozole Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Overview of drug-induced deaths in Europe - What does the data tell us?

Overview of drug-induced deaths in Europe - What does the data tell us? Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Sandoz B.V. Page 1/8 Package leaflet: Information for the user Pioglitazon Lek 15 mg, tabletten Pioglitazon Lek 30 mg, tabletten Pioglitazon Lek 45 mg, tabletten Pioglitazone Read all of this leaflet carefully

More information

Patient Information Leaflet

Patient Information Leaflet 1.1.1 1.3.1.3 Patient Information Leaflet Package leaflet: Information for the patient Prapexin 0.088 mg Tablets Prapexin 0.18 mg Tablets Prapexin 0.7 mg Tablets Pramipexole Read all of this leaflet carefully

More information